GDC-0334 is a TRPA1 antagonist for the treatment of TRPA1-mediated disease and is an oral candidate compound for the study of asthma.
| Molecular Weight | 609.49 |
| Formula | C24H19F8N5O3S |
| CAS Number | 1984824-54-5 |
| Solubility (25°C) | N/A |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related TRP Channel Products |
|---|
| GDC-6599
GDC-6599 is a first-in-class, orally effective TRPA1 inhibitor for studies related to chronic cough and asthma. |
| Acetaldehyde
Acetaldehyde is a TRP anchor protein 1 (TRPA1) agonist that is converted to non-toxic acetic acid by acetaldehyde dehydrogenase (ALDH). |
| Adenosine 5′-diphosphoribose sodium
Adenosine 5′-diphosphoribose sodium is a metabolite of nicotinamide adenine nucleotides (NAD+), as well as a potent intracellular Ca2+-permeable cation TRPM2 channel activator, and enhances autophagy. |
| JNJ-28583113
JNJ-28583113 is a brain-permeable TRPM2 antagonist and blocks phosphorylation of GSK3α and β subunits by inhibiting TRPM2. In addition, JNJ-28583113 inhibits cytokine release from microglia in response to pro-inflammatory stimuli. It has the function of protecting cells from oxidative stress-induced cell death. |
| L-R4W2 TFA
L-R4W2 TFA is a potent antagonist of vanilloid receptor 1 (VR1, TRPV1), with an IC50 of 0.1 μM. L-R4W2 TFA may act as a potent analgesic. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
